Hangzhou Biotest BiotechLtd Past Earnings Performance
Past criteria checks 1/6
Hangzhou Biotest BiotechLtd's earnings have been declining at an average annual rate of -23.5%, while the Biotechs industry saw earnings growing at 5.9% annually. Revenues have been declining at an average rate of 13.6% per year. Hangzhou Biotest BiotechLtd's return on equity is 4.3%, and it has net margins of 20.1%.
Key information
-23.5%
Earnings growth rate
-28.3%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | -13.6% |
| Return on equity | 4.3% |
| Net Margin | 20.1% |
| Last Earnings Update | 30 Sep 2024 |
Revenue & Expenses Breakdown
How Hangzhou Biotest BiotechLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 519 | 104 | 93 | 81 |
| 30 Jun 24 | 497 | 117 | 90 | 82 |
| 31 Mar 24 | 474 | 134 | 83 | 85 |
| 31 Dec 23 | 442 | 107 | 83 | 80 |
| 30 Sep 23 | 457 | -20 | 81 | 59 |
| 30 Jun 23 | 589 | 90 | 78 | 67 |
| 31 Mar 23 | 988 | 293 | 78 | 99 |
| 31 Dec 22 | 1,901 | 774 | 81 | 108 |
| 30 Sep 22 | 2,071 | 999 | 81 | 117 |
| 30 Jun 22 | 2,184 | 1,010 | 83 | 104 |
| 31 Mar 22 | 2,344 | 1,093 | 76 | 69 |
| 31 Dec 21 | 1,818 | 834 | 73 | 62 |
| 30 Sep 21 | 1,725 | 798 | 51 | 53 |
| 30 Jun 21 | 1,530 | 701 | 47 | 50 |
| 31 Mar 21 | 1,110 | 517 | 48 | 44 |
| 31 Dec 20 | 865 | 435 | 46 | 41 |
| 31 Dec 19 | 209 | 28 | 39 | 17 |
| 31 Dec 18 | 180 | 19 | 34 | 10 |
| 31 Dec 17 | 122 | 4 | 28 | 11 |
Quality Earnings: 688767 has a high level of non-cash earnings.
Growing Profit Margin: 688767 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688767's earnings have declined by 23.5% per year over the past 5 years.
Accelerating Growth: 688767 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 688767 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (0.08%).
Return on Equity
High ROE: 688767's Return on Equity (4.3%) is considered low.